Biochem/physiol Actions
JNJ-10198409 is a potent ATP-competitive inhibitor of Platelet-Derived Growth Factor receptor tyrosine kinase (PDGF-RTK) with both antiangiogenic and a direct tumor cell antiproliferative activity. It is selective for PDGF-β kinase with IC50 values of 4.2 nM for PDGF-β and 45 nM for PDGF-α kinase.
JNJ-10198409 is an ATP-competitive Platelet-Derived Growth Factor Receptor-beta (PDGFR-β) inhibitor.
Features and Benefits
This compound is a featured product for Kinase Phosphatase Biology research. Click here to discover more featured Kinase Phosphatase Biology products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the PAF Receptor and PDGFR pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
| Quality Level | 100 |
| assay | ≥98% (HPLC) |
| form | solid |
| color | off-white |
| solubility | DMSO: >10 mg/mL,H2O: <2 mg/mL |
| originator | Johnson & Johnson |
| storage temp. | −20°C |
| SMILES string | COc1cc2Cc3c(Nc4cccc(F)c4)n[nH]c3-c2cc1OC |
| InChI | 1S/C18H16FN3O2/c1-23-15-7-10-6-14-17(13(10)9-16(15)24-2)21-22-18(14)20-12-5-3-4-11(19)8-12/h3-5,7-9H,6H2,1-2H3,(H2,20,21,22) |
| InChI key | ZDNURMVOKAERHZ-UHFFFAOYSA-N |
